Emerging urinary biomarkers in the diagnosis of acute kidney injury.
Emerging urinary biomarkers in the diagnosis of acute kidney injury.
复制标题
DOI：
10.1517/17530059.2.4.387
复制
发表时间：
2008-04-01
期刊：
影响因子：
--
通讯作者：
Devarajan, Prasad
中科院分区：
文献类型：
--
作者：
Devarajan, Prasad
背景：急性肾损伤(AKI)是临床医学中常见且严重的问题。AKI早期生物标记物的缺乏导致了潜在有效疗法的启动延迟。目的：鉴定AKI的新型尿液生物标记物，目前已进入生物标记物发现的临床阶段。方法：查阅PubMed、Medline 2000年至今的文献。结果/结论：最有前景的AKI生物标志物包括中性粒细胞明胶酶相关的Lipocalin、IL-18、肾脏损伤分子-1和肝型脂肪酸结合蛋白。在大规模队列和多种临床情况的临床样本中验证这些生物标记物的敏感性和特异性的研究正在进行中，商业工具的开发为其测量提供了便利。
BACKGROUND: Acute kidney injury (AKI) represents a common and devastating problem in clinical medicine. The lack of early biomarkers for AKI has led to a delay in initiating potentially effective therapies. OBJECTIVE: Identification of novel urinary biomarkers for AKI that have progressed to the clinical phase of the biomarker discovery process. METHODS: A literature review (PubMed, MedLine) from 2000 to the present. RESULTS/CONCLUSIONS;: The most promising AKI biomarkers include neutrophil gelatinase-associated lipocalin, IL-18, kidney injury molecule-1 and liver-type fatty acid binding protein. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from large cohorts and from multiple clinical situations are in progress, facilitated by the development of commercial tools for their measurement.